{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:42:44Z","timestamp":1792212164324,"version":"4.4.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7658-26","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:09:19Z","timestamp":1792015759000},"source":"Crossref","is-referenced-by-count":0,"title":["Utility of Blood Neutrophil to Diagnose Bacterial Infections under Satralizumab Treatment for Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: A Report of Two Cases"],"prefix":"10.2169","author":[{"given":"Hiroshi","family":"Kuroda","sequence":"first","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Japan"},{"name":"Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan"},{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Japan"},{"name":"Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan"},{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sagae","sequence":"additional","affiliation":[{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Uryu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Southern TOHOKU Research Institute for Neuroscience Southern TOHOKU General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med 387: 631-639, 2022.","DOI":"10.1056\/NEJMra1904655"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol 17: 759-773, 2021.","DOI":"10.1038\/s41582-021-00568-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381: 2114-2124, 2019.","DOI":"10.1056\/NEJMoa1901747"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19: 402-412, 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10: 720-727, 2014.","DOI":"10.1038\/nrrheum.2014.127"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Li X, Zhao C. Interleukin-6 in neuroimmunological disorders: pathophysiology and therapeutic advances with satralizumab. Autoimmun Rev 24: 103826, 2025.","DOI":"10.1016\/j.autrev.2025.103826"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Greenberg BM, Fujihara K, Weinshenker B, et al. Analysis of infection rates in neuromyelitis optica spectrum disorder: comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord 99: 106444, 2025.","DOI":"10.1016\/j.msard.2025.106444"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fujita R, Aratake Y, Nakata K, Fujii C, Kondo T. Urosepsis risk in neuromyelitis optica spectrum disorder patients administered satralizumab. Intern Med 62: 3317-3320, 2023.","DOI":"10.2169\/internalmedicine.1642-23"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamamura T, Isobe N, Kawachi I, et al. Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 30-month interim analysis of post-marketing surveillance. Neurol Ther 14: 2429-2451, 2025.","DOI":"10.1007\/s40120-025-00799-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fujiwara H, Nishimoto N, Hamano Y, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 19: 64-68, 2009.","DOI":"10.3109\/s10165-008-0111-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yanagawa Y, Hirano Y, Kato H, Iba T. The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep 2012, 2012.","DOI":"10.1136\/bcr.02.2012.5835"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nagai Y, Yokogawa N, Shimada K, Sugii S. Utility of the neutrophil-to-lymphocyte ratio for predicting bacterial infection in patients with rheumatoid arthritis receiving tocilizumab. Rheumatol Int 40: 2039-2046, 2020.","DOI":"10.1007\/s00296-020-04705-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsuoka T, Araki M, Lin Y, et al. Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 11, 2024.","DOI":"10.1212\/NXI.0000000000200173"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kuroda H, Fujihara K, Kaneko K, et al. Changes in blood cells and complements during relapse prevention therapies for aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Int J Mol Sci 27: 951, 2026.","DOI":"10.3390\/ijms27020951"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bari SF, Khan A, Lawson T. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013, 2013.","DOI":"10.1136\/bcr-2013-010423"},{"key":"16","unstructured":"16. Abramson N, Melton B. Leukocytosis: basics of clinical assessment. Am Fam Physician 62: 2053-2060, 2000."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7658-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:16:13Z","timestamp":1792210573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7658-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7658-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7658-26"}}